Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
467
datasets available to search
ShareScore release 0.9.0
Dataset results
467 results for “Trial Data”
Data from: Sharing of clinical trial data among trialists: a cross sectional survey
Objective: To investigate clinical trialists' opinions and experiences of sharing of clinical trial data with investigators who are not directly collaborating with the research team. Design and setting: Cross sectional, web based survey. Participants: Clinical trialists who were corresponding authors of clinical trials published in 2010 or 2011 in one of six general medical journals with the highest impact factor in 2011. Main outcome measures: Support for and prevalence of data sharing through data repositories and in response to individual requests, concerns with data sharing through repositories, and reasons for granting or denying requests. Results: Of 683 potential respondents, 317 completed the survey (response rate 46%). In principle, 236 (74%) thought that sharing de-identified data through data repositories should be required, and 229 (72%) thought that investigators should be required to share de-identified data in response to individual requests. In practice, only 56 (18%) indicated that they were required by the trial funder to deposit the trial data in a repository; of these 32 (57%) had done so. In all, 149 respondents (47%) had received an individual request to share their clinical trial data; of these, 115 (77%) had granted and 56 (38%) had denied at least one request. Respondents' most common concerns about data sharing were related to appropriate data use, investigator or funder interests, and protection of research subjects. Conclusions: We found strong support for sharing clinical trial data among corresponding authors of recently published trials in high impact general medical journals who responded to our survey, including a willingness to share data, although several practical concerns were identified.
Data from: Trial-results reporting and academic medical centers.
To the Editor: Reporting of aggregate results helps mitigate disclosure biases affecting medical research. Although the reporting of summary results is currently mandated by the Food and Drug Administration Amendments Act of 2007 (FDAAA), published findings suggest underreporting. Two recent proposals are aimed at improving public reporting of aggregate results. These are a Notice of Proposed Rulemaking (NPRM) to expand FDAAA requirements to include the results of trials of unapproved products, and a draft policy requiring the results of all National Institutes of Health (NIH)-funded trials, including those not subject to the FDAAA.
Data from: The Fear Reduction Exercised Early (FREE) approach to management of low back pain in general practice: a pragmatic cluster-randomised controlled trial
Background: Effective and cost-effective primary care treatments for low back pain (LBP) are required to reduce the burden of the world's most disabling condition. This study aimed to compare the clinical effectiveness and cost-effectiveness of the Fear Reduction Exercised Early (FREE) approach to LBP (intervention) with usual general practitioner (GP) care (control). Methods and findings: This pragmatic, cluster-randomised controlled trial with process evaluation and parallel economic evaluation was conducted in the Hutt Valley, New Zealand. Eight general practices were randomly assigned (stratified by practice size) with a 1:1 ratio to intervention (4 practices; 34 GPs) or control group (4 practices; 29 GPs). Adults presenting to these GPs with LBP as their primary complaint were recruited. GPs in the intervention practices were trained in the FREE approach, and patients presenting to these practices received care based on the FREE approach. The FREE approach restructures LBP consultations to prioritise early identification and management of barriers to recovery. GPs in control practices did not receive specific training for this study, and patients presenting to these practices received usual care. Between 23 September 2016 and 31 July 2017, 140 eligible patients presented to intervention practices (126 enrolled) and 110 eligible patients presented to control practices (100 enrolled). Patient mean age was 46.1 years (SD 14.4), and 46% were female. The duration of LBP was less than 6 weeks in 88% of patients. Primary outcome was change from baseline in patient participant Roland Morris Disability Questionnaire (RMDQ) score at 6 months. Secondary patient outcomes included pain, satisfaction, and psychosocial indices. GP outcomes included attitudes, knowledge, confidence, and GP LBP management behaviour. There was active and passive surveillance of potential harms. Patients and outcome assessors were blind to group assignment. Analysis followed intention-to-treat principles. A total of 122 (97%) patients from 32 GPs in the intervention group and 99 (99%) patients from 25 GPs in the control group were included in the primary outcome analysis. At 6 months, the groups did not significantly differ on the primary outcome (adjusted mean RMDQ score difference 0.57, 95% CI −0.64 to 1.78; p = 0.354) or secondary patient outcomes. The RMDQ difference met the predefined criterion to indicate noninferiority. One control group participant experienced an activity-related gluteal tear, with no other adverse events recorded. Intervention group GPs had improvements in attitudes, knowledge, and confidence compared with control group GPs. Intervention group GP LBP management behaviour became more guideline concordant than the control group. In cost-effectiveness, the intervention dominated control with lower costs and higher Quality-Adjusted Life Year (QALY) gains. Limitations of this study were that although adequately powered for primary outcome assessment, the study was not powered for evaluating some employment, healthcare use, and economic outcomes. It was also not possible for research nurses (responsible for patient recruitment) to be masked on group allocation for practices. Conclusions: Findings from this study suggest that the FREE approach improves GP concordance with LBP guideline recommendations but does not improve patient recovery outcomes compared with usual care. The FREE approach may reduce unnecessary healthcare use and produce economic benefits. Work participation or health resource use should be considered for primary outcome assessment in future trials of undifferentiated LBP.
Data from: Ibobbly mobile health intervention for suicide prevention in Australian Indigenous youth: a pilot randomised controlled trial
Objectives: Rates of youth suicide in Australian Indigenous communities are four times the national youth average and demand innovative interventions. Historical and persistent disadvantage is coupled with multiple barriers to help-seeking. Mobile phone applications offer the opportunity to deliver therapeutic interventions directly to individuals in remote communities.The pilot study aimed to evaluate the effectiveness of a self-help mobile app (ibobbly) targeting suicidal ideation, depression, psychological distress, and impulsivity among Indigenous youth in remote Australia. Setting: Remote and very remote communities in the Kimberley region of north Western Australia Participants: Indigenous Australians aged 18-35 years. Interventions: 61 participants were recruited and randomised to receive either an app (ibobbly) which delivered acceptance-based therapy over 6 weeks or were waitlisted for 6 weeks and then received the app for the following 6 weeks. Primary and secondary outcome measures: The primary outcome was the Depressive Symptom Inventory – Suicidality Subscale (DSI-SS) to identify the frequency and intensity of suicidal ideation in the previous weeks. Secondary outcomes were the Patient Health Questionnaire 9 (PHQ-9), the Kessler Psychological Distress Scale (K10), and the Barratt Impulsivity Scale (BIS-11). Results: Although pre- post-intervention change on the (DSI-SS) was significant in the ibobbly arm (t=2•40; df=58•1; p=0•0195), this difference was not significant compared to the waitlist arm (t=1•05; df=57•8; p=0•2962). However, participants in the ibobbly group showed substantial and statistically significant reductions in PHQ-9 and K10 scores compared to waitlist. No differences were observed in impulsivity. Waitlist participants improved after 6 weeks of app use. Conclusions: Apps for suicide prevention reduce distress and depression but do not show significant reductions on suicide ideation or impulsivity. A feasible and acceptable means of lowering symptoms for mental health disorders in remote communities is via appropriately designed self-help apps. Trial Registration: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12613000104752.
Data from: Prevalence, associated factors, awareness, treatment, and control of hypertension: findings from a cross sectional study conducted as a part of a community based intervention trial in Surkhet, Mid-western region of Nepal
Background Hypertension is one of the leading public health problems globally. About half of the deaths from cardiovascular diseases were attributed to hypertension in 2008. Reduction of blood pressure to normal range is one of the major challenges in preventing complications and future burden of cardiovascular diseases. Therefore, this study aims to determine prevalence, awareness, treatment and control of hypertension and its associated factors in Nepal. Methods This was a community based cross-sectional study conducted as a part of a community based intervention trial in Birendranagar Municipality of Surkhet district located at the Mid-western region of Nepal. We enrolled 1159 subjects aged 30 years and above. Out of 12 wards (administrative unit), four wards were selected randomly. Three hundred participants were recruited from each selected ward. Trained enumerator collected socio-demographic, anthropometric, and clinical data using standard STEPS questionnaires. Results Out of all participants, women were 71% and mean age was 47±12.6 years. The overall prevalence of hypertension was 38.9% (95% CI: 36–41.7) while age and sex adjusted prevalence was 40.6%. The hypertension was present in 48.1% (95% CI: 45.2–50.9) of men and 35.2% (95% CI: 32.4–37.9)] of women. Male gender (OR = 1.49), older age (OR = 1.04 per year), Dalit caste (OR = 1.71), past history of cigarettes smoking (OR = 2.78), current alcohol consumption (OR = 1.75), and raised body mass index (OR = 1.17 per unit) were identified as significant factors associated with hypertension. Of total hypertensive respondents, 53.4% (95% CI: 48.7–58) were aware, 29% (95% CI: 24.8–33.1) were receiving treatment for high blood pressure, and 8.2% (95% CI: 5.6–10.7) had controlled blood pressure. The awareness, treatment, and control status were worse in younger participants. Conclusions The study revealed high prevalence with low awareness, treatment, and control of hypertension in Nepal. Gender, age, ethnicity, smoking, drinking alcohol, and body mass index were associated with hypertension. Immediate public health and individual measures are warranted to reduce future burden of cardiovascular diseases.
Data from: Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind, randomised controlled trial.
BACKGROUND: Retained placenta is associated with post-partum haemorrhage. Meta-analysis has suggested that umbilical injection of oxytocin could increase placental expulsion without the need for a surgeon or anaesthetic. We assessed the effect of high-dose umbilical vein oxytocin as a treatment for retained placenta. METHODS: In this double-blind, placebo-controlled trial, haemodynamically stable women with a retained placenta for more than 30 min were recruited from 13 sites in the UK, Uganda, and Pakistan. 577 women were randomly assigned by a computer-generated randomisation list stratified by centre to 30 mL saline containing either 50 IU oxytocin (n=292) or 5 mL water (n=285), which was injected into the placenta through an umbilical vein catheter. All trial participants, study workers, and data handlers were masked to individual allocations. The primary outcome was the need for manual removal of the placenta. Analysis was by intention to treat. This study is registered, number ISRCTN 13204258. FINDINGS: The primary outcome was recorded for all participants. We detected no difference between the groups in the need for manual removal of placenta (oxytocin 179/292 [61.3%] vs placebo 177/285 [62.1%]; relative risk 0.98, 95% CI 0.87-1.12; p=0.84). The need for manual removal was higher in the UK (overall 250/361 [69%]) than in Uganda (90/190 [47%]) or Pakistan (16/26 [62%]). Adverse events did not differ between the two groups. INTERPRETATION: Umbilical oxytocin has no clinically significant effect on the need for manual removal for women with retained placenta. FUNDING: WHO, WellBeing of Women, Pakistan Higher Education Commission.
Data repository for "Scalable Quantum Monte Carlo with Direct-Product Trial Wave Functions"
<p>This Zenodo deposit provides a comprehensive collection of raw data, processed data, and scripts associated with the research paper available at <a href="https://arxiv.org/abs/2306.15186" target="_new">https://arxiv.org/abs/2306.15186</a>.</p> <p>Contents:</p> <p>- data.zip includes all the QMCpack inputs and outputs, which can be used in the blocking analysis to obtain the AFQMC energy. Processed Data "SI for DP-MSD-AFQMC.xlsx" contains the AFQMC results after the blocking analysis in XLSX format. "SI for DP-MSD-AFQMC.xlsx" also includes the energies from all other methods presented in the paper.</p> <p>- scripts.zip contains all the Python scripts used in running calculations for the paper. This includes scripts to generate LAS-AFQMC and CAS-AFQMC trials (under scripts/utils) in QMCpack format, as well as inputs for each compound.</p>
Betula ermanii range-wide provenance trial: Survival, height, diameter, and productivity data
<p>Understanding the response of <em>Betula ermanii</em> populations to climate change is crucial for conservation efforts. Range-wide provenance trials provide valuable insights into local adaptation and phenotypic plasticity, aiding in the maintenance of productivity in boreal and alpine forest ecosystems. This study aimed to evaluate the impact of climate change on survival and productivity of <em>B. ermanii</em>, and to formulate conservation strategies for future climates. Using survival and growth data from provenance trials, models were developed and applied to projected climate scenarios obtained from WorldClim. Results indicated that populations at the southern edge and thermal limit experienced more pronounced declines in survival and productivity compared to others. Particularly, the southern-edge population struggled to survive <em>in situ</em> under severe climate warming, while the high-altitude edge population faced challenges in surviving <em>ex situ</em>. These findings emphasize the necessity of integrating both <em>in situ</em> and <em>ex situ</em> conservation measures tailored to source populations and the severity of climate change. Range-wide provenance trial data provide valuable insights into how climatic responses affect populations, guiding conservation efforts for <em>Betula ermanii</em> in the face of changing environmental conditions.</p>
data_Statistical_Review_of_Animal_trials
<p>This data set contains the number of reviewed proposals by the Animal Welfare Act committee in Berlin in 2020. </p>
Data set from: Robot-Assisted Gait Training in Patients with Multiple Sclerosis: A Randomized Controlled Crossover Trial.
<p>Data set from the paper "Robot-Assisted Gait Training in Patients with Multiple Sclerosis: A Randomized Controlled Crossover Trial" doi: <a href="https://dx.doi.org/10.3390%2Fmedicina57070713">10.3390/medicina57070713</a></p>
Data set supplementing "Determinants of Laypersons' Trust in Medical Decision Aids: Randomized Controlled Trial"
<p>This is the de-identified data set used to conduct the analyses in the preprint submitted to JMIR Human Factors under the title "Determinants of Laypersons’ Trust in Medical Decision Aids: Randomized Controlled Trial" (<a href="https://doi.org/10.2196/35219">https://doi.org/10.2196/35219</a>).</p> <p>This dataset contains 494 respondents' appraisals of a fictitious case vignette. They received support from a decision aid (that always disagreed with participants' first appraisal) showing a mock symptom checker logo, a decision aid framed as anthropomorphic or as an AI. Their second appraisal - taking into account the symptom checker advice - was collected again. </p> <p>Additionally, the data contains participants'</p> <ul> <li>age</li> <li>gender</li> <li>education</li> <li>medical training</li> <li>propensity to trust</li> <li>eHealth Literacy</li> <li>certainty in their appraisals</li> <li>trust in the decision aid</li> </ul>
Data from 36 fungicide trials on grape downy mildew across Europe 2012-2019
<p>The data set comprises records of disease incidence and yield from untreated and treated plots.</p> <p>The data is provided as both a tab-separated text file and a binary R data file. The R files provides code to read and plot the data. The plot produced is also provided as a PNG file.</p> <p>The field trials were conducted by BASF, Germany.</p> <p><em>Details</em><br> The PlantPart column refers to leaves (LEAF), inflorescences (RACEME) and grape clusters (FRUIT). The disease (GDM) was assessed by two methods (Method column), designated P%FREQ and P%INF:<br> • P%INF: Intensity of attack was obtained as a visual estimation of the percentage of each plant part (leaf, raceme or grape cluster) affected by disease.<br> • P%FREQ: Frequency of attack was obtained as the number of infected plant parts (leaf, raceme or grape cluster). The frequency was expressed as a percentage of the number sampled.</p> <p> </p>
Data for "Patient-Important Outcomes Other Than Mortality in Contemporary ICU Trials: A Scoping Review"
<p>This upload contains the final datasets analyzed in the manuscript "Patient-Important Outcomes Other Than Mortality in Contemporary ICU Trials: A Scoping Review", published in Critical Care Medicine, 2022 (https://doi.org/10.1097/CCM.0000000000005637). The Supplemental Digital Content included with the primary manuscript includes a data dictionary, additional details, and the analysis code used.</p>
Trial Data
<p>The purpose of this data is to test out a certain pipeline. Please use this for trial only</p>
Dataset for Spence et al., "Patient consent to publication and data sharing in industry and NIH-funded clinical trials" (Trials 2018 19:269).
<p>Dataset for our journal publication (Spence et al. 2018 <a href="https://doi.org/10.1186/s13063-018-2651-2">https://doi.org/10.1186/s13063-018-2651-2</a>). This dataset contains</p> <ul> <li>Informed consent forms (ICFs) for 98 industry-funded clinical trials</li> <li>Informed consent forms (ICFs) for 46 NIH-funded clinical trials</li> <li>Our extraction datasheet</li> </ul>
Data From: ChatGPT versus expert feedback on clinical reasoning questions and their effect on learning: a randomized controlled trial
<p>Dataset Info</p> <p><strong>1) Immediate Test</strong><br>- The first row of the dataset identifies the columns.<br>- Column A represents the participants’ iDs.<br>- Column B represents the participants’ assigned group [0: Control (ExpertFeedback) 1: Intervention (ChatGPTFeedback)].<br>- Column C represents the genders of the participants (1: Female, 2: Male).<br>- Column D represents the first-year repetition status of the participants. (0: No, 1: Yes)<br>- Column E to H represent the scores in four different uncomplicated urinary tract infection (UTI) Key-Features Questions Items separately. <br>- Column I represents the total scores in uncomplicated UTI Key-Features Questions Items. <br>- Column J to M represent the scores in four different complicated UTI Key-Features Questions Items separately. <br>- Column N represents the total scores in complicated UTI Key-Features Questions Items. <br>- Column O to R represent the scores in four different pyelonephritis Key-Features Questions Items separately. <br>- Column S represents the total scores in pyelonephritis Key-Features Questions Items. <br>- Column T represents the total scores in immediate test. </p> <p><strong>2) Delayed Test</strong><br>- The first row of the dataset identifies the columns.<br>- Column A represents the participants iDs.<br>- Column B represents the participants’ assigned group [0: Control (ExpertFeedback) 1: Intervention (ChatGPTFeedback)].<br>- Column C represents the genders of the participants (1: Female, 2: Male).<br>- Column D represents the first-year repetition status of the participants. (0: No, 1: Yes)<br>- Column E to H represent the scores in four different uncomplicated urinary tract infection (UTI) Key-Features Questions Items separately. <br>- Column I represents the total scores in uncomplicated UTI Key-Features Questions Items. <br>- Column J to M represent the scores in four different complicated UTI Key-Features Questions Items separately. <br>- Column N represents the total scores in complicated UTI Key-Features Questions Items. <br>- Column O to R represent the scores in four different pyelonephritis Key-Features Questions Items separately. <br>- Column S represents the total scores in pyelonephritis Key-Features Questions Items. <br>- Column T represents the total scores in delayed test. </p> <p><strong>3) Pre-Intervention Survey on Critical Approach to AI</strong><br>- The first row of the dataset identifies the columns.<br>- Column A represents the participants iDs.<br>- Column B represents the participants’ assigned group [0: Control (ExpertFeedback) 1: Intervention (ChatGPTFeedback)].<br>- Column C represents the genders of the participants (1: Female, 2: Male).<br>- Column D represents the first-year repetition status of the participants (0: No, 1: Yes).<br>- Column E to J represent the responses of the participants to survey questions before the intervention. Each column is evaluated on a scale from 1 to 7. As it progresses from 1 to 7, the agreement status of participants to survey questions increases. (1: No agreement at all, 7: completely agree)</p> <p><strong>4) Post-Intervention Survey on Critical Approach to AI</strong><br>- The first row of the dataset identifies the columns.<br>- Column A represents the participants iDs.<br>- Column B represents the participants’ assigned group [0: Control (ExpertFeedback) 1: Intervention (ChatGPTFeedback)].<br>- Column C represents the genders of the participants (1: Female, 2: Male).<br>- Column D represents the first-year repetition status of the participants (0: No, 1: Yes).<br>- Column E to J represent the evaluation of the participants to survey questions after intervention. Each column is evaluated on a scale from 1 to 7. As it progresses from 1 to 7, the agreement status of participants to survey questions increases. (1: No agreement at all, 7: completely agree)</p>
Data from: Plant population and maize grain yield: a global systematic review of rainfed trials
Maize (Zea mays L.) productivity has increased globally as a result of improved genetics and agronomic practices. Plant population and row spacing are two key agronomic factors known to have a strong influence on maize grain yield. A systematic review was conducted to investigate the effects of plant population on maize grain yield, differentiating between rainfall regions, N input, and soil tillage system (conventional tillage [CT] and no-tillage [NT]). Data were extracted from 64 peer-reviewed articles reporting on rainfed field trials, representing 13 countries and 127 trial locations. In arid environments, maize grain yield was low (mean maize grain yield = 2448 kg ha−1) across all plant populations with no clear response to plant population. Variation in maize grain yield was high in semiarid environments where the polynomial regression (p < 0.001, n = 951) had a maximum point at ∼140,000 plants ha−1, which reflected a maize grain yield of 9000 kg ha−1. In subhumid environments, maize grain yield had a positive response to plant population (p < 0.001). Maize grain yield increased for both CT and NT systems as plant population increased. In high-N-input (r2 = 0.19, p < 0.001, n = 2 018) production systems, the response of plant population to applied N was weaker than in medium-N-input (r2 = 0.49, p < 0.001, n = 680) systems. There exists a need for more metadata to be analyzed to provide improved recommendations for optimizing plant populations across different climatic conditions and rainfed maize production systems. Overall, the importance of optimizing plant population to local environmental conditions and farming systems is illustrated.
Clinical Trial Transparency and Data-Sharing Among Bio-Pharmaceutical Companies and the Role of Company Size, Location, and Product Type: A Cross-Sectional Descriptive Analysis
<p><b>Objective</b>: To examine company characteristics associated with better transparency and to apply a tool used to measure and improve clinical trial transparency among large companies and drugs, to smaller companies and biologics.</p> <p><b>Design</b>: Cross-sectional descriptive analysis.</p> <p><b>Setting and participants. </b>Novel drugs and biologics FDA approved in 2016 and 2017, and their company sponsors.</p> <p>Using established Good Pharma Scorecard (GPS) measures, companies and products were evaluated on their clinical trial registration, results dissemination, and FDA Amendments Act (FDAAA) implementation; Companies were ranked using these measures and a multi-component data sharing measure. Associations between company transparency scores with company size (large vs non-large), location (US vs non-US), and sponsored product type (drug vs biologic) were also examined. 26% of products (16/62) had publicly available results for all clinical trials supporting their FDA approval and 67% (39/58) had public results for trials in patients by 6 months after their FDA approval; 58% (32/55) were FDAAA compliant. Large companies were significantly more transparent than non-large companies (overall median transparency score of 95% [IQR 91-100] vs 59% [IQR 41-70], p<0.001), attributable to higher FDAAA compliance (median of 100% [IQR 88-100] vs 57% [0-100], p=0.01) and better data sharing (median of 100% [IQR 80-100] vs 20% [IQR 20-40], p<0.01). No significant differences were observed by company location or product type. It was feasible to apply the GPS transparency measures and ranking tool to non-large companies and biologics. Large companies are significantly more transparent than non-large companies, driven by better data sharing procedures and implementation of FDAAA trial reporting requirements. Greater research transparency is needed, particularly among non-large companies, to maximize the benefits of research for patient care and scientific innovation. </p>
Data from: Field trials of chemical suppression of embryonic cane toads (Rhinella marina) by older conspecifics
<p>1. Laboratory experiments have shown that the viability of embryos of the invasive cane toad (<i>Rhinella marina</i>) can be reduced by exposure to chemical cues from older conspecific larvae. These effects (very strong in laboratory trials) may offer an exciting new approach to controlling this problematic invasive species in Australia. However, the degree to which the method works in natural environments has yet to be assessed.</p> <p>2. Our experiments in the laboratory and in semi-natural outdoor waterbodies show that chemical cues from tadpoles do indeed suppress the growth, development and survival of conspecific larvae that are exposed as embryos and do so in a dose-dependent manner; higher tadpole densities cause greater suppression of embryos.</p> <p>3. In semi-natural outdoor waterbodies, suppressor-exposed tadpoles were less than half as likely to survive to metamorphosis as were controls, and were much smaller when they did so and hence, less likely to survive the metamorph stage. Additionally, female cane toads were less likely to oviposit in a waterbody containing free-ranging (but not cage-enclosed) tadpoles, suggesting that the presence of tadpoles (rather than the chemical cues they produce) may discourage oviposition.</p> <p>4. Broadly, our results suggest that the suppression effect documented in laboratory studies does indeed occur in the field also, and hence that we may be able to translate that approach to develop new and more effective ways to reduce rates of recruitment of peri-urban populations of cane toads in their invasive range.</p>
data_bci_keio_trial
<p>this is just a trial of zenodo as a wepage to upload all the data gathered during the brain experiments performed for my masters degree thesis research</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.